The study that nitroglycerin treatment may increase response to chemotherapy via inhibitions of hypoxia-inducible factor-1 pathway in patients with breast cancer.

• Project/Area Number: 22591420
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: General surgery
• Research Institution: Tohoku University
• Principal Investigator: AMARI Masakazu 東北大学, 大学院・医学系研究科, 准教授 (50400312)
• Co-Investigator(Kenkyū-buntansha): ISHIDA Takanori 東北大学, 大学院・医学系研究科, 准教授 (00292318) ; KAWAI Masaaki 東北大学, 大学院・医学系研究科, 助教 (80513530) ; OHUCHI Noriaki 東北大学, 大学院・医学系研究科, 教授 (90203710) ; YASUDA Hiroyasu 東北大学, 大学院・医学系研究科, 非常勤講師 (90396482) ; 梅田 みか(渡辺みか) (大内 憲明) 東北大学, 大学病院, 准教授 (20292344)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 乳腺外科学 / 一酸化窒素供与剤 / HIF-1α / HK II / 低酸素癌細胞 / 一酸化窒素 / 乳がん / 化学療法 / 上乗せ効 / 上乗せ効果

Research Abstract

This study suggest that HK II is induced by HIF-1α and plays important roles in the proliferation and/or progression of breast cancer by increased glycolytic activity. HK II status is considered a potent prognostic factor in human breast cancer patients.